Markus Warmuth - Mar 1, 2022 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
President & CEO, Director
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/2/2022, 05:26 PM
Previous filing
Jun 23, 2021
Next filing
Jan 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +316K $0.00 316K Mar 1, 2022 Common Stock 316K $13.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.